Stoke Therapeutics, Inc   Report issue

For profit Phase 2
Founded: Bedford MA United States (2014)

Organization Overview

First Clinical Trial
2020
NCT04442295
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Stoke Therapeutics, Inc

Active Ingredients

Drugs in Phase 2 Trials (1)

stk-001 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Epilepsies, Myoclonic (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1